DK1328271T3 - Behandling af neurologiske og neurofysiologiske sygdomme - Google Patents

Behandling af neurologiske og neurofysiologiske sygdomme

Info

Publication number: DK1328271T3
Authority: DK; Denmark
Prior art keywords: npy; activity; treatment; reduction; functionally active
Prior art date: 2000-10-27

Application number

DK01988583T

Other languages

English (en)

Inventor

Horsten Stephan Von

Hans-Ulrich Demuth

Matthias Hoffmann

Susanne Kruber

Huu Phuc Nguyen

Ants Kask

Original Assignee

Probiodrug Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-10-27

Filing date

2001-10-29

Publication date

2008-10-13

2001-10-29 Application filed by Probiodrug Ag filed Critical Probiodrug Ag

2008-10-13 Application granted granted Critical

2008-10-13 Publication of DK1328271T3 publication Critical patent/DK1328271T3/da

Links

201000010099 disease Diseases 0.000 title abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
230000001537 neural effect Effects 0.000 title abstract 2
230000000926 neurological effect Effects 0.000 title abstract 2
101710151321 Melanostatin Proteins 0.000 abstract 3
102400000064 Neuropeptide Y Human genes 0.000 abstract 3
230000000694 effects Effects 0.000 abstract 3
URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 abstract 3
208000019901 Anxiety disease Diseases 0.000 abstract 1
102100027936 Attractin Human genes 0.000 abstract 1
101710134735 Attractin Proteins 0.000 abstract 1
208000000094 Chronic Pain Diseases 0.000 abstract 1
102000004190 Enzymes Human genes 0.000 abstract 1
108090000790 Enzymes Proteins 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
241001465754 Metazoa Species 0.000 abstract 1
208000002193 Pain Diseases 0.000 abstract 1
102000001708 Protein Isoforms Human genes 0.000 abstract 1
108010029485 Protein Isoforms Proteins 0.000 abstract 1
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract 1
208000005392 Spasm Diseases 0.000 abstract 1
230000000202 analgesic effect Effects 0.000 abstract 1
230000001430 anti-depressive effect Effects 0.000 abstract 1
230000036506 anxiety Effects 0.000 abstract 1
239000002249 anxiolytic agent Substances 0.000 abstract 1
230000000949 anxiolytic effect Effects 0.000 abstract 1
210000004556 brain Anatomy 0.000 abstract 1
230000015556 catabolic process Effects 0.000 abstract 1
230000001364 causal effect Effects 0.000 abstract 1
238000006731 degradation reaction Methods 0.000 abstract 1
230000003001 depressive effect Effects 0.000 abstract 1
206010015037 epilepsy Diseases 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
206010022437 insomnia Diseases 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
108010043412 neuropeptide Y-Y1 receptor Proteins 0.000 abstract 1
BPGXUIVWLQTVLZ-OFGSCBOVSA-N neuropeptide y(npy) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 BPGXUIVWLQTVLZ-OFGSCBOVSA-N 0.000 abstract 1
230000002035 prolonged effect Effects 0.000 abstract 1
201000000980 schizophrenia Diseases 0.000 abstract 1
239000000758 substrate Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Addiction (AREA)
Immunology (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Nutrition Science (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Anesthesiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

DK01988583T 2000-10-27 2001-10-29 Behandling af neurologiske og neurofysiologiske sygdomme DK1328271T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US24403600P	2000-10-27	2000-10-27
PCT/EP2001/012479 WO2002034243A2 (en)	2000-10-27	2001-10-29	Method for the treatment of neurological and neuropsychological disorders

Publications (1)

Publication Number	Publication Date
DK1328271T3 true DK1328271T3 (da)	2008-10-13

Family

ID=22921137

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK01988583T DK1328271T3 (da)	2000-10-27	2001-10-29	Behandling af neurologiske og neurofysiologiske sygdomme

Country Status (19)

Country	Link
US (1)	US20040043919A1 (da)
EP (2)	EP1328271B1 (da)
JP (2)	JP2004512300A (da)
KR (2)	KR20030096227A (da)
CN (3)	CN1471392A (da)
AT (1)	ATE399008T1 (da)
AU (3)	AU2177302A (da)
BR (2)	BR0114921A (da)
CA (3)	CA2422889C (da)
CY (1)	CY1108336T1 (da)
DE (1)	DE60134563D1 (da)
DK (1)	DK1328271T3 (da)
ES (1)	ES2309108T3 (da)
IL (4)	IL155157A0 (da)
NO (2)	NO20031849L (da)
PT (1)	PT1328271E (da)
RU (3)	RU2003115614A (da)
WO (2)	WO2002034242A2 (da)
ZA (2)	ZA200302590B (da)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL135068A (en) *	1997-09-29	2004-03-28	Point Therapeutics Inc	Stimulation of hematopoietic cells in vitro
US6979697B1 (en) *	1998-08-21	2005-12-27	Point Therapeutics, Inc.	Regulation of substrate activity
US6890904B1 (en) *	1999-05-25	2005-05-10	Point Therapeutics, Inc.	Anti-tumor agents
KR20030096227A (ko) *	2000-10-27	2003-12-24	프로비오드룩 아게	신경 및 신경정신 질환의 치료방법
US7132104B1 (en)	2000-10-27	2006-11-07	Probiodrug Ag	Modulation of central nervous system (CNS) dipeptidyl peptidase IV (DPIV) -like activity for the treatment of neurological and neuropsychological disorders
DE60222667T2 (de)	2001-06-27	2008-07-17	Smithkline Beecham Corp.	Fluorpyrrolidine als dipeptidylpeptidaseinhibitoren
KR20040105853A (ko)	2002-04-08	2004-12-16	토렌트 파마슈티칼스 리미티드	티아졸리딘-4-카르보니트릴 및 유사체와디펩티딜-펩티다아제 억제제로서의 용도
JP2006506442A (ja) *	2002-07-09	2006-02-23	ポイントセラピューティクス，インコーポレイテッド	ボロプロリン化合物併用療法
US20040242566A1 (en)	2003-03-25	2004-12-02	Syrrx, Inc.	Dipeptidyl peptidase inhibitors
MXPA05011861A (es)	2003-05-05	2006-02-17	Probiodrug Ag	Uso de efectores de ciclasas de glutamato y glutaminil.
NZ572274A (en)	2003-05-05	2009-06-26	Probiodrug Ag	Use of effectors of glutaminyl and glutamate cyclases
JP2007511467A (ja)	2003-05-14	2007-05-10	タケダサンディエゴインコーポレイテッド	ジペプチジルペプチダーゼインヒビター
MXPA06001601A (es)	2003-08-13	2006-08-25	Takeda Pharmaceutical	Derivados de 4-pirimidona y su uso como inhibidores de dipeptidilpeptidasa.
US7678909B1 (en)	2003-08-13	2010-03-16	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US7169926B1 (en)	2003-08-13	2007-01-30	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
WO2005026148A1 (en)	2003-09-08	2005-03-24	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
EA010108B1 (ru)	2003-10-15	2008-06-30	Пробиодруг Аг	Применение эффекторов глутаминил- и глутаматциклаз
US7732446B1 (en)	2004-03-11	2010-06-08	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
CN102127057A (zh)	2004-03-15	2011-07-20	武田药品工业株式会社	二肽基肽酶抑制剂
WO2005118555A1 (en)	2004-06-04	2005-12-15	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
WO2006019965A2 (en)	2004-07-16	2006-02-23	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
US20060063719A1 (en) *	2004-09-21	2006-03-23	Point Therapeutics, Inc.	Methods for treating diabetes
EP1828192B1 (en)	2004-12-21	2014-12-03	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
SI1942898T2 (sl)	2005-09-14	2014-08-29	Takeda Pharmaceutical Company Limited	Dipeptidil-peptidazni inhibitorji za zdravljenje diabetesa
EP1924567B1 (en)	2005-09-16	2012-08-22	Takeda Pharmaceutical Company Limited	Process for the preparation of pyrimidinedione derivatives
WO2007112347A1 (en)	2006-03-28	2007-10-04	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
AU2007235876A1 (en)	2006-04-12	2007-10-18	Probiodrug Ag	Enzyme inhibitors
US8324383B2 (en)	2006-09-13	2012-12-04	Takeda Pharmaceutical Company Limited	Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en)	2006-11-29	2008-10-01	Takeda Pharmaceutical	Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en)	2007-03-13	2012-01-10	Takeda Pharmaceuticals Company Limited	Weekly administration of dipeptidyl peptidase inhibitors
RU2350331C1 (ru) *	2007-07-10	2009-03-27	Государственное образовательное учреждение высшего профессионального образования "Мордовский государственный университет им. Н.П. Огарева"	Способ лечения невроза навязчивых состояний
RU2350330C1 (ru) *	2007-11-13	2009-03-27	Государственное образовательное учреждение высшего профессионального образования "Мордовский государственный университет им. Н.П. Огарева"	Способ лечения истерического невроза
JO2870B1 (en)	2008-11-13	2015-03-15	ميرك شارب اند دوهم كورب	Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
EP2473047B1 (en)	2009-09-02	2014-08-13	Merck Sharp & Dohme Corp.	Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2011079778A1 (en)	2009-12-30	2011-07-07	China Shanghai Fochon Pharmaceutical Co Ltd	3-(3-aminopiperidin-1-yl)-5-oxo-1,2,4-triazine derivates as dipeptidyl peptidase iv(dpp-iv) inhibitors
WO2011103256A1 (en)	2010-02-22	2011-08-25	Merck Sharp & Dohme Corp.	Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
US8980929B2 (en)	2010-05-21	2015-03-17	Merck Sharp & Dohme Corp.	Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
WO2013122920A1 (en)	2012-02-17	2013-08-22	Merck Sharp & Dohme Corp.	Dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
US9668969B1 (en)	2012-02-22	2017-06-06	Arturo Solis Herrera	Methods of using QIAPINE
US9315508B2 (en)	2012-07-23	2016-04-19	Merck Sharp & Dohme Corp.	Treating diabetes with dipeptidyl peptidase-IV inhibitors
CN107213465A (zh) *	2017-06-23	2017-09-29	武汉大学	二肽基肽酶iv抑制剂在制备防治癫痫的药物中的应用
CN119380997B (zh) *	2024-12-27	2025-03-21	内蒙古医科大学附属医院(内蒙古自治区心血管研究所)	一种神经内科康复程度评价方法及系统

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US25023A (en) *		1859-08-09		Improved device for making electro-magnetic currents, constant or intermittent
US2961377A (en) *	1957-08-05	1960-11-22	Us Vitamin Pharm Corp	Oral anti-diabetic compositions and methods
US3174901A (en) *	1963-01-31	1965-03-23	Jan Marcel Didier Aron Samuel	Process for the oral treatment of diabetes
US3879541A (en) *	1970-03-03	1975-04-22	Bayer Ag	Antihyperglycemic methods and compositions
US3960949A (en) *	1971-04-02	1976-06-01	Schering Aktiengesellschaft	1,2-Biguanides
CH602612A5 (da) *	1974-10-11	1978-07-31	Hoffmann La Roche
US4935493A (en) *	1987-10-06	1990-06-19	E. I. Du Pont De Nemours And Company	Protease inhibitors
US5433955A (en) *	1989-01-23	1995-07-18	Akzo N.V.	Site specific in vivo activation of therapeutic drugs
DE4039415A1 (de) *	1990-02-03	1991-08-08	Boehringer Mannheim Gmbh	Verfahren zur herstellung rekombinanter proteine ohne n-terminalen methioninrest
US5462928A (en) *	1990-04-14	1995-10-31	New England Medical Center Hospitals, Inc.	Inhibitors of dipeptidyl-aminopeptidase type IV
IL106998A0 (en) *	1992-09-17	1993-12-28	Univ Florida	Brain-enhanced delivery of neuroactive peptides by sequential metabolism
IL111785A0 (en) *	1993-12-03	1995-01-24	Ferring Bv	Dp-iv inhibitors and pharmaceutical compositions containing them
US5705483A (en) *	1993-12-09	1998-01-06	Eli Lilly And Company	Glucagon-like insulinotropic peptides, compositions and methods
US5543396A (en) *	1994-04-28	1996-08-06	Georgia Tech Research Corp.	Proline phosphonate derivatives
US5512549A (en) *	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5614379A (en) *	1995-04-26	1997-03-25	Eli Lilly And Company	Process for preparing anti-obesity protein
DE19616486C5 (de) *	1996-04-25	2016-06-30	Royalty Pharma Collection Trust	Verfahren zur Senkung des Blutglukosespiegels in Säugern
US6006753A (en) *	1996-08-30	1999-12-28	Eli Lilly And Company	Use of GLP-1 or analogs to abolish catabolic changes after surgery
US5827898A (en) *	1996-10-07	1998-10-27	Shaman Pharmaceuticals, Inc.	Use of bisphenolic compounds to treat type II diabetes
US6011155A (en) *	1996-11-07	2000-01-04	Novartis Ag	N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6803357B1 (en) *	1998-02-02	2004-10-12	New England Medical Center Hospitals, Inc.	Method of regulating glucose metabolism, and reagents related thereto
WO1999046272A1 (en) *	1998-03-09	1999-09-16	Fondatech Benelux N.V.	Serine peptidase modulators
DE19823831A1 (de) *	1998-05-28	1999-12-02	Probiodrug Ges Fuer Arzneim	Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE19834591A1 (de) *	1998-07-31	2000-02-03	Probiodrug Ges Fuer Arzneim	Verfahren zur Steigerung des Blutglukosespiegels in Säugern
AU3960400A (en) *	1999-03-05	2000-09-28	Molteni L. E C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A.	Use of metformin in the preparation of pharmaceutical compositions capable of inhibiting the enzyme dipeptidyl peptidase iv
US6110949A (en) *	1999-06-24	2000-08-29	Novartis Ag	N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6107317A (en) *	1999-06-24	2000-08-22	Novartis Ag	N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6172081B1 (en) *	1999-06-24	2001-01-09	Novartis Ag	Tetrahydroisoquinoline 3-carboxamide derivatives
DK1283735T4 (da) *	2000-03-31	2013-02-04	Royalty Pharma Collection Trust	Fremgangsmåde til forbedring signalering af øceller ved diabetes mellitus og til forebyggelse deraf
KR20030096227A (ko) *	2000-10-27	2003-12-24	프로비오드룩 아게	신경 및 신경정신 질환의 치료방법

2001
- 2001-10-29 KR KR10-2003-7005769A patent/KR20030096227A/ko not_active Ceased
- 2001-10-29 IL IL15515701A patent/IL155157A0/xx unknown
- 2001-10-29 JP JP2002537297A patent/JP2004512300A/ja active Pending
- 2001-10-29 CN CNA01817857XA patent/CN1471392A/zh active Pending
- 2001-10-29 CN CNA2006101219115A patent/CN101143217A/zh active Pending
- 2001-10-29 ZA ZA200302590A patent/ZA200302590B/en unknown
- 2001-10-29 BR BR0114921-0A patent/BR0114921A/pt not_active Application Discontinuation
- 2001-10-29 ES ES01988583T patent/ES2309108T3/es not_active Expired - Lifetime
- 2001-10-29 CA CA2422889A patent/CA2422889C/en not_active Expired - Fee Related
- 2001-10-29 US US10/415,263 patent/US20040043919A1/en not_active Abandoned
- 2001-10-29 AT AT01988583T patent/ATE399008T1/de active
- 2001-10-29 CN CNB018180671A patent/CN1278683C/zh not_active Expired - Fee Related
- 2001-10-29 WO PCT/EP2001/012478 patent/WO2002034242A2/en not_active Ceased
- 2001-10-29 DK DK01988583T patent/DK1328271T3/da active
- 2001-10-29 RU RU2003115614/14A patent/RU2003115614A/ru not_active Application Discontinuation
- 2001-10-29 AU AU2177302A patent/AU2177302A/xx active Pending
- 2001-10-29 IL IL15511601A patent/IL155116A0/xx unknown
- 2001-10-29 AU AU2002221773A patent/AU2002221773B2/en not_active Ceased
- 2001-10-29 EP EP01988583A patent/EP1328271B1/en not_active Expired - Lifetime
- 2001-10-29 BR BR0114924-5A patent/BR0114924A/pt not_active IP Right Cessation
- 2001-10-29 CA CA002689012A patent/CA2689012A1/en not_active Abandoned
- 2001-10-29 CA CA002424475A patent/CA2424475A1/en not_active Abandoned
- 2001-10-29 DE DE60134563T patent/DE60134563D1/de not_active Expired - Lifetime
- 2001-10-29 EP EP01988582A patent/EP1328270A2/en not_active Withdrawn
- 2001-10-29 KR KR10-2003-7005718A patent/KR20040025875A/ko not_active Withdrawn
- 2001-10-29 JP JP2002537296A patent/JP2004512299A/ja not_active Withdrawn
- 2001-10-29 PT PT01988583T patent/PT1328271E/pt unknown
- 2001-10-29 WO PCT/EP2001/012479 patent/WO2002034243A2/en not_active Ceased
- 2001-10-29 ZA ZA200302394A patent/ZA200302394B/en unknown
- 2001-10-29 RU RU2003115622/14A patent/RU2286149C2/ru not_active IP Right Cessation
- 2001-10-29 AU AU2002227898A patent/AU2002227898A1/en not_active Abandoned
2003
- 2003-03-27 IL IL155116A patent/IL155116A/en not_active IP Right Cessation
- 2003-04-24 NO NO20031849A patent/NO20031849L/no unknown
- 2003-04-25 NO NO20031867A patent/NO20031867L/no not_active Application Discontinuation
2006
- 2006-06-20 RU RU2006122179/15A patent/RU2416406C2/ru not_active IP Right Cessation
2008
- 2008-09-11 CY CY20081100982T patent/CY1108336T1/el unknown
2009
- 2009-02-11 IL IL196994A patent/IL196994A0/en unknown

Also Published As

Publication number	Publication date
HK1062643A1 (en)	2004-11-19
RU2006122179A (ru)	2007-12-27
WO2002034242A2 (en)	2002-05-02
WO2002034242A3 (en)	2003-01-30
AU2002227898A1 (en)	2002-05-06
ATE399008T1 (de)	2008-07-15
WO2002034243A2 (en)	2002-05-02
CN1471393A (zh)	2004-01-28
CA2689012A1 (en)	2002-05-02
RU2003115614A (ru)	2004-10-27
RU2416406C2 (ru)	2011-04-20
NO20031849L (no)	2003-06-23
IL196994A0 (en)	2011-07-31
NO20031867D0 (no)	2003-04-25
CA2424475A1 (en)	2002-05-02
RU2286149C2 (ru)	2006-10-27
NO20031867L (no)	2003-06-19
EP1328271A2 (en)	2003-07-23
BR0114924A (pt)	2003-12-23
US20040043919A1 (en)	2004-03-04
CN1471392A (zh)	2004-01-28
CA2422889A1 (en)	2002-05-02
WO2002034243A3 (en)	2003-01-30
BR0114921A (pt)	2003-12-23
CY1108336T1 (el)	2014-02-12
EP1328271B1 (en)	2008-06-25
NO20031849D0 (no)	2003-04-24
AU2002221773B2 (en)	2005-12-22
IL155116A0 (en)	2003-10-31
AU2177302A (en)	2002-05-06
JP2004512299A (ja)	2004-04-22
IL155116A (en)	2009-09-01
ES2309108T3 (es)	2008-12-16
JP2004512300A (ja)	2004-04-22
PT1328271E (pt)	2008-08-26
ZA200302394B (en)	2004-03-29
EP1328270A2 (en)	2003-07-23
DE60134563D1 (de)	2008-08-07
IL155157A0 (en)	2003-10-31
CN1278683C (zh)	2006-10-11
CA2422889C (en)	2010-01-26
CN101143217A (zh)	2008-03-19
KR20030096227A (ko)	2003-12-24
KR20040025875A (ko)	2004-03-26
ZA200302590B (en)	2004-04-02

Publication	Publication Date	Title
DK1328271T3 (da)	2008-10-13	Behandling af neurologiske og neurofysiologiske sygdomme
DE60027431D1 (de)	2006-05-24	Verwendung von p38 MAPK Inhibitoren in der Behandlung von Augenkrankheiten
ATE298566T1 (de)	2005-07-15	Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
DK0971713T3 (da)	2003-09-22	Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser
DE60324449D1 (de)	2008-12-11	Inhibitoren der phosphodiesterase der zyklischen n, und deren verwendung in therapie
AR019011A1 (es)	2001-12-26	Inhibidores de las caspasas, composiciones farmaceuticas que comprenden estos inhibidores, metodos para inhibir la actividad de caspasa, disminuir laproduccion de 161f, disminuir la produccion de ifn-gama y para tratar interleukina 1, enfermedades mediadas por apoptosis e interferon-gama usando dich
NO20044470L (no)	2004-11-04	Terapeutisk anvendelse av selektive PDE 10 inhibitorer
ATE207352T1 (de)	2001-11-15	Nicht-allosterische gaba a agonisten zur behandlung von schlafstörungen
ATE356804T1 (de)	2007-04-15	Inhibitoren von mitotischem kinesin
DE60222302D1 (de)	2007-10-18	Inhibitoren von mitotischem kinesin
MXPA05006359A (es)	2006-02-08	Tratamiento de la enfermedad a traves de inhibidores peptidos antimicrobianos.
DE60228278D1 (de)	2008-09-25	Die verwendung von potenten, selektiven und nontoxischen c-kithemmern zur behandlung von interstitieller blasenentzündung
ATE356634T1 (de)	2007-04-15	Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln
DE60008753D1 (de)	2004-04-08	Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
ATE334693T1 (de)	2006-08-15	Verwendung von tyrosine-kinase inhibitoren zur behandlung von cns krankheiten
DE60209886D1 (de)	2006-05-11	Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen
ATE409469T1 (de)	2008-10-15	Verwendung von 2,2,3,3, tetramethylcyclopropane carbonsäure derivaten zur behandlung von psychiatrischen störungen
HUP0401154A2 (hu)	2004-10-28	NK-1 receptor antagonisták használata kutyák, macskák és lovak nemkívánatos viselkedésének módosítására